European Heart Journal-Cardiovascular Pharmacotherapy

Papers
(The TQCC of European Heart Journal-Cardiovascular Pharmacotherapy is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study61
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients56
Comments on—The noradrenaline dosing in the new 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure48
Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohor45
Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials44
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials40
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study39
Early initiation of SGLT2 inhibitors after acute myocardial infarction38
Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials36
Current evidence and future perspective for the management of left-sided prosthetic valve thrombosis33
Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study32
Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?29
Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Reg28
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia28
Editorial on incidence and outcomes of transient new onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis27
Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy27
Treatment with dual antiplatelet therapy after an acute coronary event may often be tailor-made for the patient25
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlle24
Need for more evidence of safety in the pharmacological therapy of anaemia in chronic kidney disease: a cardiovascular perspective24
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study24
Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials23
Long-term cardiovascular outcomes after orlistat therapy in patients with obesity: a nationwide, propensity-score matched cohort study23
Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy23
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy22
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis21
Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial21
Inhibition of interleukin-1 or -6 after myocardial infarction: pros, cons, and future perspectives21
New ways of mitigating aldosterone in cardiorenal disease20
Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data20
Subcutaneous furosemide patch: heart failure decongestion ‘from the comfort of your home’20
Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy20
Cardiovascular prevention and risk factors19
All about clinical trials19
Late breaking clinical trials at ACC 2218
De-escalation versus shortening of dual antiplatelet therapy18
Dosage of direct oral anticoagulants during dual and triple antithrombotic therapy: a focus on the net clinical benefit18
Association of guideline-directed medical therapy adherence with outcomes after fractional flow reserve-based deferral of revascularization17
Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis17
Tocilizumab, blood cells, and mild COVID-19: delayed vascular protection by interleukin blockade?17
Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-17
Correction to: Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial16
Long-term Antiplatelet Monotherapy After PCI: Searching for the Smart Choice16
News in cardiovascular pharmacotherapy from the ACC.24 Meeting16
Focus on different lipid-lowering treatment and genetic testing for optimal pharmacotherapy use in the clinic15
Pharmacotherapy of patients with heart failure and atrial fibrillation: let's get the evidence!15
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis15
Different aspects of giving the optimal antiplatelet treatment15
Photoinduced skin reactions of cardiovascular drugs—a systematic review15
Incidence, associated outcomes, and predictors of upper gastrointestinal bleeding following acute myocardial infarction: a SWEDEHEART-based nationwide cohort study15
Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: apost hocanalysis of the ATHENA trial15
Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials15
Chronic coronary syndrome and new-onset atrial fibrillation or venous thromboembolism: how best to manage antithrombotic therapy strategies15
Initial statin dose after myocardial infarction and long-term cardiovascular outcomes14
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 202314
The dual endothelin-1 antagonist aprocitentan alleviates mitochondrial oxidative stress in human cardiac fibroblasts14
Apixaban outcomes in atrial fibrillation patients with a single-dose reduction criterion: ASPIRE 1-year results14
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry14
Stroke risk stratifications according to CHA2DS2-VASc vs. CHA2DS2-VA in patients with Atrial Fibrillation: insights from the GLORIA-AF registry14
Effects of renin–angiotensin system inhibitor type and dosage on survival after transcatheter aortic valve implantation13
Focus on different aspects of atrial fibrillation13
Are NOACs always the best strategy in elderly AF patients?13
What's new in pharmacotherapy at ESC Congress 2023?12
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial12
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 202212
Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study12
Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis12
Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation12
Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis12
Extensive LDL-cholesterol lowering by PCSK9 inhibitor on the risk of venous thrombosis11
Who requires longer-term anticoagulation therapy for venous thromboembolism from the perspective of precision medicine?11
Is the TIME study on antihypertensive therapy and chronotropic effects on cardiovascular outcomes a pragmatic trial?11
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled tr11
New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study11
Inotropes and mortality in patients with cardiogenic shock: an instrumental variable analysis from the SWEDEHEART registry11
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy10
RNA-targeted therapeutics in cardiovascular disease: the time is now10
Immunomodulatory effect of different statin regimens on regulatory T-cells in patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials10
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial10
Outcomes after delayed primary percutaneous coronary intervention vs. pharmaco-invasive strategy in ST-segment elevation myocardial infarction in Norway10
Cardiovascular disease and cardiovascular pharmacotherapy: the challenges and the research continue10
Corrigendum to: Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharm10
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease9
Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study9
Cardio-renal benefits of sodium–glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence9
Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study9
Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial9
Sodium–glucose cotransporter 2 inhibitor use in early-phase acute coronary syndrome with severe heart failure9
Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study9
Does LDL-C determination method affect statin prescribing for primary prevention? A register-based study in Southern Denmark9
Response to—Current evidence and future perspective for the management of left sided prosthetic valve thrombosis8
FLOW trial stopped early due to evidence of renal protection with semaglutide8
Treating patients with anticoagulants and antiplatelet drugs is always a balance between risk for thrombosis vs. risk for bleeding8
0.071202993392944